Sumitomo Mitsui Asset Management Company LTD decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 267,468 shares of the company’s stock after selling 5,099 shares during the quarter. Sumitomo Mitsui Asset Management Company LTD’s holdings in Johnson & Johnson were worth $34,773,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. BlackRock Inc. grew its position in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. Janus Henderson Group PLC grew its position in Johnson & Johnson by 717.9% in the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after purchasing an additional 3,289,763 shares during the period. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares during the period. Parametric Portfolio Associates LLC grew its position in Johnson & Johnson by 47.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after purchasing an additional 2,581,562 shares during the period. Finally, Harbour Capital Advisors LLC grew its position in Johnson & Johnson by 13,327.8% in the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after purchasing an additional 2,482,843 shares during the period. 65.70% of the stock is owned by institutional investors.

Several analysts recently issued reports on JNJ shares. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research report on Monday, September 18th. Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their price objective for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. Citigroup started coverage on Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. Finally, UBS Group restated a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research note on Saturday, September 30th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $145.69.

Shares of Johnson & Johnson (JNJ) opened at $144.79 on Friday. The company has a market capitalization of $388,980.00, a price-to-earnings ratio of 25.14, a PEG ratio of 2.67 and a beta of 0.80. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $145.68. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.68 EPS. research analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.32%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is 58.33%.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Stake Lowered by Sumitomo Mitsui Asset Management Company LTD” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-stake-lowered-by-sumitomo-mitsui-asset-management-company-ltd/1804241.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.